Clik here to view.
PMC Group International宣布收购法国制药公司
新泽西州芒特劳雷尔 (美国商业资讯) — PMC Group Inc.的独立分支机构PMC Group International Inc.旗下的全资子公司PMC Group France宣布收购法国Isochem...
View ArticleClik here to view.
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1...
CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash. Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3...
View ArticleClik here to view.
ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu...
LAUSANNE, Schweiz ADC Therapeutics (ADCT), ein onkologisches Biotech-Unternehmen, das sich auf die Entwicklung von geschützten Antikörper-Wirkstoff-Konjugaten (Antibody Drug Conjugates, ADCs) zur...
View ArticleClik here to view.
ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
スイス・ローザンヌ （ビジネスワイヤ） — 主要ながんを標的にした専有的な抗体薬物複合体（ADC）の開発を専門とするオンコロジー創薬／開発企業のADCセラピューティクス（ADCT）は本日、リンパ腫と白血病の重要な亜型でADCT-301（camidanlumab...
View ArticleClik here to view.
武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据，该试验评估ADCETRIS® (brentuximab...
马萨诸塞州剑桥、日本大阪和华盛顿州博瑟尔 (美国商业资讯) – 武田药品工业株式会社(TSE:4502)和Seattle Genetics, Inc. (NASDAQ: SGEN)今天宣布，3期ECHELON-1临床试验的数据将于2017年12月10日星期天在第59届美国血液学会(ASH)年会的全体科学会议上呈报，该项试验评估ADCETRIS (brentuximab...
View ArticleClik here to view.
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with...
TOKYO, BASKING RIDGE, N.J. & LOS ANGELES Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc. (Nasdaq: PBYI) have announced a preclinical research...
View ArticleClik here to view.
ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
スイス・ローザンヌ （ビジネスワイヤ） — 主要ながんを標的にした専有的な抗体薬物複合体（ADC）の開発を専門とするオンコロジー創薬／開発企業のADCセラピューティクス（ADCT）は本日、リンパ腫と白血病の重要な亜型でADCT-402（loncastuximab...
View ArticleClik here to view.
Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for...
PRINCETON, N.J. & OSAKA, Japan Bristol-Myers Squibb Company (NYSE:BMY) and Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; “Ono”) announced an...
View ArticleClik here to view.
Chi-Med Initiates Fruquintinib U.S. Clinical Trials
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent...
View ArticleClik here to view.
武田薬品とシアトル・ジェネティクスが進行期ホジキンリンパ腫のフロントライン治療でアドセトリス（ブレンツキシマブ・ベドチン）を評価する第3相ECHELON-...
米マサチューセッツ州ケンブリッジ & 大阪 & ワシントン州ボセル （ビジネスワイヤ）– 武田薬品工業株式会社（TSE:4502）とシアトル・ジェネティクス（NASDAQ:...
View ArticleClik here to view.
Dr. Reddy’s announces it has reached a settlement with the US Government...
HYDERABAD, India & PRINCETON, N.J. (BSE: 500124, NSE: DRREDDY, NYSE: RDY)—The US subsidiary of Dr. Reddy’s Laboratories Ltd. announced today that it has reached a settlement with the US...
View ArticleClik here to view.
Samsung Bioepis’ SB3 Trastuzumab Biosimilar Candidate Accepted for Review by...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) under the 351(k)...
View ArticleClik here to view.
Generex Confirms Receipt of $700,000 USD License Fee from Shenzhen BioScien...
MIRAMAR, Fla. Generex Biotechnology Corporation (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (www.generex.com) today confirmed its receipt of the $700,000 USD up-front license fee (net...
View ArticleClik here to view.
Dr. Xiaoxiang Chen Joins Harbour BioMed as Executive Vice President, Head of...
SHANGHAI, ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. Harbour BioMed announced today the appointment of Dr. Xiaoxiang Chen as Executive Vice President, Head of Clinical Development and...
View ArticleClik here to view.
和铂医药宣布任命陈小祥为和铂医药执行副总裁，临床开发和注册科学负责人
中国上海，荷兰鹿特丹和美国马萨诸塞州 和铂医药（Harbour BioMed）宣布，任命陈小祥医师为执行副总裁，临床开发和注册科学负责人。 本新闻稿包含多媒体。此处查看新闻稿全文： http://www.businesswire.com/news/home/20180103005373/zh-CN/ 陈小祥医师，和铂医药执行副总裁，临床开发和注册科学负责人 (照片：美国商业资讯)...
View ArticleClik here to view.
Illumina and KingMed Diagnostics Partner to Develop Next-Generation...
SAN DIEGO Illumina, Inc. (NASDAQ: ILMN) and KingMed Diagnostics (SSE: 603882.SS) today announced an agreement to jointly develop novel oncology and hereditary disease testing applications utilizing...
View ArticleClik here to view.
Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement...
SHANGHAI & ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. Harbour BioMed announced today that it has licensed its patented H2L2 transgenic mouse platform for generating fully human...
View ArticleClik here to view.
和铂医药授权百济神州使用其全人源单克隆抗体转基因小鼠平台开发多种全人源单克隆抗体新药
中国上海，荷兰鹿特丹和美国马萨诸塞州剑桥 和铂医药（Harbour BioMed）宣布，已授权百济神州（BeiGene Ltd., NASDAQ: BGNE）, 一家处于商业化阶段的生物医药公司，专注于开发和商业化用于癌症治疗的创新型分子靶向和肿瘤免疫药物, 使用其拥有全球专利技术的H2L2转基因小鼠平台，开发全人源单克隆抗体创新药物。...
View ArticleClik here to view.
GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics...
CHICAGO GE Healthcare has entered into a strategic, long-term partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop and co-market digital clinical decision support solutions. The...
View ArticleClik here to view.
和铂医药合作开发全人源抗体片段用于新一代CAR-T细胞免疫治疗
中国上海，荷兰鹿特丹和美国马萨诸塞州剑桥 (美国商业资讯)– 和铂医药今日宣布与艺妙神州医疗科技签署合作协议，开发全人源单克隆抗体片段用于新一代嵌合抗原受体T细胞（CAR-T）细胞免疫治疗。艺妙神州是一家专注于开发CAR-T疗法以治疗血液肿瘤和实体肿瘤的生物科技公司。...
View Article